N
News Analysis
manilatimes.net

www.manilatimes.net ·

Olumlu

scancell receives fda fast track designation for iscib1 in advanced melanoma and provides data update from its scope phase 2 study

TAX_DISEASE_CANCERWB_1406_DISEASESWB_1431_CANCERWB_621_HEALTH_NUTRITION_AND_POPULATION

manilatimes.net sitesinde haberin tamamını oku

Haberin tamamı orijinal yayıncı sitesinde. Burada sadece başlık ve çok kısa özet gösterilir.

scancell receives fda fast track designation for iscib1 in advanced melanoma and provides data update from its scope phase 2 study | manilatimes.net — News Analysis